CAM
GANX icon

Cresset Asset Management’s Gain Therapeutics GANX Stock Holding History

Cresset Asset Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Hold
160,000
– – ﹤0.01% 1250
2025
Q4 		$515K Buy
+160,000
New +$427K ﹤0.01% 1054

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Cresset Asset Management's GANX Position: Q1 2026 in Review

Cresset Asset Management held its Gain Therapeutics (GANX) position steady in Q1 2026 at 160,000 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

Cresset Asset Management first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $515K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Cresset Asset Management held 160,000 shares of Gain Therapeutics worth $310K as of Q1 2026.
  • Cresset Asset Management left its Gain Therapeutics share count unchanged in Q1 2026.
  • Gain Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1250 holding.
  • Cresset Asset Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Cresset Asset Management's Gain Therapeutics position peaked at $515K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.